Items tagged with Access
WikiLeaks publication of complete, final Trans-Pacific Partnership Intellectual Property text confirms pact would raise costs, put medicines out of reach (post)
WASHINGTON, D.C. – WikiLeaks’ publication today of the final Trans-Pacific Partnership (TPP) Intellectual Property chapter text verifies that the pact would harm public health by blocking patient access to lifesaving medicines, Public Citizen said today. The latest leak of a secret TPP text reveals how the TPP would roll back the “May 10 Agreement” reforms brokered in 2007 between Democratic congressional leaders and the George W. Bush administration. It also reveals the contentious “death sentence” clause on biologics, or biotech drugs, which roiled TPP talks in Maui and Atlanta.
LDCs be damned: USTR and Big Pharma seeks to eviscerate Least Developed Countries' insulation from pharmaceutical monopolies (post)
October 12, 2015 -- In November of 2001, at the height of the global AIDS pandemic, every WTO member country in the world, including the United States, voted unanimously in the Doha Declaration on the TRIPS Agreement and Public Health that WTO Least Developed Countries members should be granted an unconditional extension of any obligation to grant or enforce patents, data protections, or exclusive marketing rights on pharmaceutical products. These countries desperately needed access to affordable generic medicines and freedom from the pillage of Big Pharma's monopoly pricing. This sensible and humane transition policy was confirmed by votes of the WTO TRIPS Council and General Council in 2002.
WTO paper could spark new ideas on TRIPS special compulsory licence for medicines export (post)
A carefully agreed 2003 waiver from international intellectual property trade rules to allow export of medicines made under compulsory licence to benefit needy countries has been quietly implemented by a large number of World Trade Organization members, according to a new analytical paper from the WTO. The analysis explores the limited use of the waiver to date and how the situation has changed since then, providing grist for a potential fresh look at the provision at this week’s annual WTO review of IP and public health.
WTO IP committee suspended over LDC extension (post)
Informal negotiations at the World Trade Organization between least developed countries (LDCs) and some developed countries over a public health extension for LDCs could not be finalised in time to be taken to the intellectual property committee meeting today and led to a suspension of the meeting for an indeterminate time.
Essential medicines are still essential (post)
On Oct 21, WHO published the full report of the 20th Expert Committee on the Selection and Use of Essential Medicines, with its new WHO Model List of Essential Medicines (EML).
USAID to reach patients in more than 100 countries with life-saving medicine for drug-resistant tuberculosis (post)
Patients in Georgia suffering from deadly strains of multidrug-resistant tuberculosis (MDR-TB) will soon have access to potentially life-saving medication thanks to a collaboration between the U.S. Agency for International Development (USAID) and Janssen. Nearly 200 patients in Georgia will begin receiving the tuberculosis drug, SIRTURO® (bedaquiline), as part of their treatment program for MDR-TB. Georgia is classified as a high MDR-TB burden country with 48 percent of known TB cases being identified as multidrug-resistant.
At African Union–India meeting in Delhi, African leaders and India should work together to protect access to affordable medicines (post)
New Delhi, 26 October 2015—As African leaders meet with Indian Prime Minister Narendra Modi in New Delhi for an African Union-India meeting this week, Médecins Sans Frontières/Doctors Without Borders (MSF) urged African governments and India to work together to maintain trade in affordable generic medicines that is a lifeline for millions of people in India, Africa and other developing countries.
Webcast debate: "The high price of medicines" (post)
On October 26, 2015 Médecins Sans Frontières (MSF) hosted a webcast debate under the title "The high price of medicines" which unpacked important questions about why medicines prices for cancer and hepatitis C medicines are so high; why we still do not have acceptable treatment options for major killers such as tuberculosis; and how deploying new models for research and innovation that do not rely on high prices when developing new antibiotics, can be a game changer for how medicines will be developed in the future.
High-level negotiations on LDC pharma IP waiver extension at WTO (post)
Negotiations have been ongoing at the World Trade Organization over the extension of a waiver allowing least-developed countries not to grant or enforce intellectual property rights on pharmaceutical products.
MSF responds to least-developed country IP exemption deal (post)
3 November 2015, Geneva - Information has emerged that the world's poorest countries - those classified as least-developed countries (LDCs) - have been granted a 17 year exemption from implementing intellectual property provisions, such as patents, on medicines. LDCs had wanted and MSF had advocated for an exemption to be granted for as long as countries were classified as a LDC.
Page 16 of 83 · Total posts: 0
←First 15 16 17 Last→